- Report
- February 2024
- 180 Pages
Global
From €4185EUR$4,450USD£3,491GBP
- Report
- January 2022
- 181 Pages
Global
From €4185EUR$4,450USD£3,491GBP
- Report
- September 2025
- 150 Pages
Global
From €4185EUR$4,450USD£3,491GBP
- Report
- March 2025
- 371 Pages
Global
From €4185EUR$4,450USD£3,491GBP
- Report
- March 2025
- 131 Pages
Europe
From €3245EUR$3,450USD£2,707GBP
- Report
- October 2024
- 151 Pages
North America
From €3245EUR$3,450USD£2,707GBP
- Report
- August 2024
- 125 Pages
Asia Pacific
From €3245EUR$3,450USD£2,707GBP
- Report
- October 2025
- 140 Pages
Global
From €4561EUR$4,850USD£3,805GBP
- Report
- October 2025
- 188 Pages
Global
From €4561EUR$4,850USD£3,805GBP
- Report
- October 2024
- 100 Pages
Global
From €3500EUR$3,986USD£3,022GBP
- Report
- June 2023
- 263 Pages
Global
From €3386EUR$3,600USD£2,824GBP
- Report
- October 2022
- 346 Pages
Global
From €3386EUR$3,600USD£2,824GBP
- Report
- April 2026
- 150 Pages
Australia
From €4561EUR$4,850USD£3,805GBP
- Report
- April 2026
- 150 Pages
Brazil
From €4561EUR$4,850USD£3,805GBP
- Report
- April 2026
- 150 Pages
Canada
From €4561EUR$4,850USD£3,805GBP
- Report
- April 2026
- 150 Pages
Germany
From €4561EUR$4,850USD£3,805GBP
- Report
- April 2026
- 150 Pages
India
From €4561EUR$4,850USD£3,805GBP
- Report
- April 2026
- 150 Pages
Indonesia
From €4561EUR$4,850USD£3,805GBP
- Report
- April 2026
- 150 Pages
Japan
From €4561EUR$4,850USD£3,805GBP
- Report
- April 2026
- 150 Pages
Malaysia
From €4561EUR$4,850USD£3,805GBP

The Antibody Drug Conjugate (ADC) market is a subset of the biotechnology industry that focuses on the development of targeted therapies for cancer and other diseases. ADCs are composed of an antibody, a linker, and a cytotoxic drug. The antibody binds to a specific target on the surface of a cell, and the linker and drug are released when the ADC binds to the target. This allows for the delivery of a high dose of the drug to the target cell, while minimizing the damage to healthy cells.
ADCs have been used to treat a variety of cancers, including breast, ovarian, and non-small cell lung cancer. They have also been used to treat other diseases, such as autoimmune disorders and infectious diseases.
The ADC market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Seattle Genetics, ImmunoGen, Pfizer, Merck, and Novartis. Show Less Read more